The difficulties in breast cancer is to introduce NGS in clinical practice. In different cancers such as the non-small cell lung cancer, it’s a routine diagnostic test. In breast cancer, it’s quite difficult to introduce it in clinical practice. Even though, as the results of the ROME trial demonstrated that the TMB could be really crucial to increase not only progression-free survival but also overall survival...
The difficulties in breast cancer is to introduce NGS in clinical practice. In different cancers such as the non-small cell lung cancer, it’s a routine diagnostic test. In breast cancer, it’s quite difficult to introduce it in clinical practice. Even though, as the results of the ROME trial demonstrated that the TMB could be really crucial to increase not only progression-free survival but also overall survival. So we need to introduce NGS also in the clinical practice of breast cancer patients because we cannot know which patient could have high tumor mutation burden or low tumor mutation burden and the only way to know the status of tumor mutation burden is to perform NGS for all our patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
